Clinical Trials Industry News More
-
Combination 'Epigenetic' Therapy May Restore Anti-Cancer Gene Activity In Late-Stage Lung Cancer Patients
11/14/2011
A new type of therapy aimed at reversing the gene-silencing that promotes cancer-cell growth has shown promising results in a small clinical trial conducted by researchers at the Johns Hopkins Kimmel Cancer Center.
-
Del Mar Pharmaceuticals Initiates Glioblastoma Clinical Trial
10/27/2011
DelMar Pharmaceuticals today announced the initiation of the Company's planned clinical trial with its lead drug candidate, VAL-083, for the treatment of refractory glioblastoma multiforme (GBM).
-
Positive Phase III Data On Bayer’s Investigational Drug Alpharadin Show Significant Increase In Overall Survival
10/4/2011
Bayer HealthCare Pharmaceuticals recently announced positive data on its investigational drug Alpharadin (radium-223 chloride) from the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.
-
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis
9/21/2011
Novartis announced recently positive results of the first pivotal Phase III trial of ACZ885 (canakinumab) in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease.
-
RXi Pharmaceuticals Provides Positive NeuVax™ Phase 3 Clinical Trial Update
9/13/2011
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, today announced a clinical trial update on its lead program, NeuVax™ (E75 peptide vaccine with GM-CSF adjuvant), a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab (Herceptin®).
-
Aeterna Zentaris Announces Completion Of Patient Recruitment For Phase 3 Trial With Perifosine In Refractory Advanced Colorectal Cancer
8/10/2011
Aeterna Zentaris Inc (the "Company") recently announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
-
GSK And Theravance Announce Results Of Two Pivotal Phase III Studies For Relovair In COPD
6/7/2011
GlaxoSmithKline (GSK) and Theravance, Inc. recently announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with chronic obstructive pulmonary disease (COPD).
-
NIH Stops Clinical Trial On Combination Cholesterol Treatment
5/27/2011
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned.
-
Collaborative To Speed Clinical Research And Reduce Costs
5/26/2011
The Partnership to Advance Clinical electronic Research (PACeR), a broad-based health care collaborative, aims to make clinical trials faster and less expensive by identifying potential candidates more efficiently and enhancing protocol modeling and data collection.
-
Radius Announces Closing Of $91M Financing To Advance BA058 Injection Into Phase 3 Osteoporosis Study
5/25/2011
Radius Health, Inc. (“Radius”) today announced that the company has raised approximately $91M in its third financing round, including $66M in equity financing and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance LLC to a $25 million multidraw term loan facility.
This website uses cookies to ensure you get the best experience on our website. Learn more